{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:49:05Z","timestamp":1783633745860,"version":"3.55.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Substantial evidence suggests that receptor tyrosine kinases (RTKs) are overexpressed in tumors; however, few studies have focused on the prognostic value of RTKs in melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of this study is to evaluate the association between overexpression of RTKs and survival in melanoma patients based on immunohistochemistry (IHC) analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our review is registered on PROSPERO (<jats:uri>http:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:uri>), registration number CRD42021261460. Seven databases were searched, and data were extracted. We used IHC to measure the association between overexpression of RTKs and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathology in melanoma patients. Pooled analysis was conducted to assess the differences between Hazard Ratios along with 95% confidence intervals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 5,508 publications examined following the database search, 23 publications were included in this study, which included data from a total of 2,072 patients. Vascular endothelial growth factor receptor 2 (VEGF-R2) overexpression was associated with worse OS and DFS in melanoma. Furthermore, there was an association between OS and the expression of several RTKs, including epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (MET), vascular endothelial growth factor receptor 1 (VEGF-R1), and insulin-like growth factor 1 receptor (IGF-1R). There were no significant correlations between EGFR overexpression and worse DFS or PFS. EGFR overexpression was associated with worse OS cutaneous and nasal melanoma, but not uveal melanoma. However, MET overexpression was related to worse OS in both cutaneous and uveal melanoma. Furthermore, EGFR overexpression was associated with a worse OS in Europe compared to other geographic areas. Moreover, EGFR and MET overexpression showed significant prognostic value in patients with the cut-off \u201c\u226510% staining\u201d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings build concrete evidence that overexpression of RTKs is associated with poor prognosis and clinicopathology in melanoma, highlighting RTK expression has the potential to inform individualized combination therapies and accurate prognostic evaluation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.819051","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:27:00Z","timestamp":1663932420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic value of receptor tyrosine kinases in malignant melanoma patients: A systematic review and meta-analysis of immunohistochemistry"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuan","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningzheng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch","year":"2021","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2021.04.003","article-title":"The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis","author":"Versluis","year":"2021","journal-title":"Eur J Cancer (Oxford Engl"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eaav7416","DOI":"10.1126\/sciadv.aav7416","article-title":"Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms","volume":"6","author":"Aldonza","year":"2020","journal-title":"Sci Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0484-2","article-title":"A drug discovery platform to identify compounds that inhibit EGFR triple mutants","volume":"16","author":"Saraon","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2020.10.005","article-title":"Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer","volume":"496","author":"Zhang","year":"2021","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1038\/s41467-020-19575-2","article-title":"ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL","volume":"11","author":"Pietrobono","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3382","article-title":"HDAC inhibition enhances the In vivo efficacy of MEK inhibitor therapy in uveal melanoma","volume":"25","author":"Fai\u00e3o-Flores","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"Cd010383","DOI":"10.1002\/14651858.CD010383.pub3","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"3","author":"Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3216","article-title":"The HGF\/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer","volume":"23","author":"Cascone","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0252","article-title":"REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"2","author":"McShane","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy088","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): An abridged explanation and elaboration","volume":"110","author":"Sauerbrei","year":"2018","journal-title":"J Natl Cancer Institute"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Institute"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2011.09.013","article-title":"Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma","volume":"46","author":"Al-Jamal","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"B16","first-page":"1","article-title":"Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target","volume":"43","author":"All-Ericsson","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1600-0560.2011.01673.x","article-title":"EGFR in melanoma: clinical significance and potential therapeutic target","volume":"38","author":"Boone","year":"2011","journal-title":"J Cutan Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0412-4081.2012.11.007","article-title":"[Overexpression of the receptor tyrosine kinase EphA2 in choroidal melanoma: correlation with vesculogenic mimicry and prognosis]","volume":"48","author":"Chen","year":"2012","journal-title":"[Zhonghua yan ke za zhi] Chin J Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41419-019-1875-8","article-title":"Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF\/NRAS mutation status","volume":"10","author":"Das","year":"2019","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0322","article-title":"Receptors for the liver synthesized growth factors IGF-1 and HGF\/SF in uveal melanoma: intercorrelation and prognostic implications","volume":"46","author":"Economou","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200204000-00006","article-title":"Overexpression of HER-2 in thick melanoma","volume":"12","author":"Eliopoulos","year":"2002","journal-title":"Melanoma Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-011-9424-6","article-title":"Phosphorylated pVEGFR2\/KDR receptor expression in uveal melanomas: relation with HIF2\u03b1 and survival","volume":"29","author":"Giatromanolaki","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"B23","article-title":"Expression of epidermal growth factor receptor: Risk factor in uveal melanoma","volume":"41","author":"Hurks","year":"2000","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000123","article-title":"EGFR and cyclin D1 in nodular melanoma: correlation with pathohistological parameters and overall survival","volume":"24","author":"Katunaric","year":"2014","journal-title":"Melanoma Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/modpathol.2010.220","article-title":"Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases","volume":"24","author":"Langer","year":"2011","journal-title":"Modern Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ar.20736","article-title":"Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma","volume":"291","author":"Liu","year":"2008","journal-title":"Anatomical Record-Advances Integr Anat Evolutionary Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/02713680601161220","article-title":"Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-met in uveal melanoma: An immunohistochemical study","volume":"32","author":"Mallikarjuna","year":"2007","journal-title":"Curr Eye Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00511-x","article-title":"Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level","volume":"43","author":"Mo","year":"2020","journal-title":"Cell Oncol (Dordrecht)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12501","article-title":"Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma","volume":"13","author":"Monteiro","year":"2019","journal-title":"Mol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/cmr.0000000000000040","article-title":"HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma","volume":"24","author":"Nielsen","year":"2014","journal-title":"Melanoma Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0509-8","article-title":"Immunohistochemical determination of HER-2\/neu, c-kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma","volume":"130","author":"Potti","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0207019","DOI":"10.1371\/journal.pone.0207019","article-title":"Correlation of vascular endothelial growth factor subtypes and their receptors with melanoma progression: A next-generation tissue microarray (ngTMA) automated analysis","volume":"13","author":"Seyed Jafari","year":"2018","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64922-X","article-title":"Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression","volume":"160","author":"Straume","year":"2002","journal-title":"Am J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26118","article-title":"Nuclear HER3 is associated with favorable overall survival in uveal melanoma","volume":"130","author":"Trocme","year":"2012","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/pcmr.12206","article-title":"Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth","volume":"27","author":"Yoshida","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000428","article-title":"Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma","volume":"28","author":"Zhu","year":"2018","journal-title":"Melanoma Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.418","article-title":"Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas","volume":"135","author":"Wang","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.105","article-title":"MITF modulates therapeutic resistance through EGFR signaling","volume":"135","author":"Ji","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.annonc.2020.09.021","article-title":"TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma","volume":"32","author":"Albiges","year":"2021","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","article-title":"Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European organisation for research and treatment of cancer phase II trial 1317 \u2018CaboGIST\u2019","volume":"134","author":"Sch\u00f6ffski","year":"2020","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.12.015","article-title":"Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome","volume":"45","author":"Mouawad","year":"2009","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071847","article-title":"Correlation of MET and PD-L1 expression in malignant melanoma","volume":"12","author":"Song","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.1766","article-title":"Potential role of soluble c-met as a new candidate biomarker of metastatic uveal melanoma","volume":"133","author":"Barisione","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-0776","article-title":"C-met is a potentially new therapeutic target for treatment of human melanoma","volume":"13","author":"Puri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328335a916","article-title":"Correlation of clinicopathological parameters with HGF, c-met, EGFR, and IGF-1R expression in uveal melanoma","volume":"20","author":"Topcu-Yilmaz","year":"2010","journal-title":"Melanoma Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2018.v108i9.13435","article-title":"Clinical and pathological features of acral melanoma in a south African population: A retrospective study","volume":"108","author":"De Wet","year":"2018","journal-title":"South Afr Med J = Suid-Afrikaanse Tydskrif vir Geneeskunde"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz209","article-title":"BRAF, KIT, and NRAS mutations of acral melanoma in white patients","volume":"153","author":"Dika","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv294","article-title":"Melanoma thickness and survival trends in the united states, 1989 to 2009","volume":"108","author":"Shaikh","year":"2016","journal-title":"J Natl Cancer Institute"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e14790","DOI":"10.1111\/dth.14790","article-title":"Comparative study of cutaneous melanoma and its associated issues between people of African decent and caucasians","volume":"34","author":"Anaba","year":"2021","journal-title":"Dermatologic Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e6258","DOI":"10.1097\/md.0000000000006258","article-title":"Malignant melanoma in African-americans: A population-based clinical outcomes study involving 1106 African-American patients from the surveillance, epidemiology, and end result (SEER) database (1988-2011)","volume":"96","author":"Mahendraraj","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188440","article-title":"Drug tolerance to target therapy in melanoma revealed at single cell level: What next","volume":"1874","author":"Liguoro","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-017-0238-1","article-title":"Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies","volume":"5","author":"Reilley","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.819051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:27:10Z","timestamp":1663932430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.819051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":55,"alternative-id":["10.3389\/fonc.2022.819051"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.819051","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"819051"}}